Tag: Adaptive Immunity

Is abundance of B cells the best biomarker to predict immune checkpoint inhibitor response in head and neck squamous cell cancers?

In 2019, the US Food and Drug administration (FDA) approved the anti-programmed cell death (PD-1) monoclonal antibody, pembrolizumab, for the treatment of patients with relapsed or metastatic head and neck squamous cell cancers (R/M HNSCC). The PDL1-IHC 22C3 pharmDx kit was included as a companion diagnostic test to select patients with HNSCC with a combined… Continue reading Is abundance of B cells the best biomarker to predict immune checkpoint inhibitor response in head and neck squamous cell cancers?

New molecule shows promise in protecting mice from influenza

Researchers at the University of Gothenburg, Sweden, in collaboration with colleagues in China, have discovered an antibody-like molecule that can protect mice from various influenza viruses. The findings could pave the way for new treatments and the development of broader influenza vaccines. We have identified a small molecule that binds to the virus’s surface protein… Continue reading New molecule shows promise in protecting mice from influenza

Low-avidity T cells drive endogenous tumor immunity in mice and humans

Abstract T cells recognize neoepitope peptide-major histocompatibility complex class I on cancer cells. The strength (or avidity) of the T cell receptor–peptide-major histocompatibility complex class I interaction is a critical variable in immune control of cancers. Here, we analyze neoepitope-specific CD8 cells of distinct avidities and show that low-avidity T cells are the sole mediators… Continue reading Low-avidity T cells drive endogenous tumor immunity in mice and humans